Therapeutic Indications

Conferences & Courses
Cancer Targets for Antibody Therapeutics Cancer Targets for Antibody Therapeutics
January 19-20, 2015 | San Diego, CA
Cancer Targets for Antibody Therapeutics explores new directions in the discovery of emerging and challenging targets in this space – and the steps that will be required in developing these into next generation therapeutics.

Personalized Diagnostics Personalized Diagnostics
February 16-18, 2015 | San Francisco, CA
Cambridge Healthtech Institute’s Sixth Annual Personalized Diagnostics conference will take place February 16-18 in San Francisco CA.

Circulating Tumor Cells Circulating Tumor Cells
February 16-18, 2015 | San Francisco, CA
Cambridge Healthtech Institute’s Fifth Annual Circulating Tumor Cells conference taking place February 16-18 in San Francisco CA will review most everything pertaining to circulating tumor cell and cell-free DNA from markers of choice for clinical use, ch




Life Science Media Library
Understanding EMT: Mechanisms and Metastasis to MET Understanding EMT: Mechanisms and Metastasis to MET
February 20, 2012 |
Epethelial Mesenchymal Transition (EMT) plays a critical role in cancer cells, but understanding of its mechanisms is incomplete. EMT causes cells to develop increased motility, invasiveness, and greater resistance to apoptosis. These changes make the cells more like stem cells, allowing them to self renew. This course provides a framework of the underlying molecular mechanisms while addressing stem cells, and cancer progression, cMET and their activity as anti-metastasis agents, and the Mesenchymal-Epethelial Transition (MET) as an essential process for tumor re-initiation, colonization, and metastasis.
CTCs from Bench to Bed CTCs from Bench to Bed
February 20, 2012 |
This course will focus on validation of CTC research data for clinical practice, correlations between CTCs, diagnosis and responses to therapy.
Targeting Cancer Stem Cells Targeting Cancer Stem Cells
November 3, 2011 |
Cancer stem cells (CSCs) have been identified in several types of cancer, and may play a role in tumorigenic growth, metastasis, and therapeutic resistance. New anticancer therapeutics are being developed that will inhibit tumor growth and reduce tumor-initiating cell frequency, improving clinical cancer therapy. The development of new agents that block key CSC pathways will be described, as well as a novel assay for tracking CSCs in cell populations without the need to isolate them, and a CSC screening strategy for discovering therapeutic antibodies.




Publications, Reports, & Whitepapers
Vaccines: The End of Illness
This report analyzes recent trends in medicinal chemistry and evaluates their significance for advancing R&D productivity. We consider technological modalities and market dynamics, with an emphasis on outsourcing and user views on the implications of current practices.
Ocular Disorders: Rising Therapeutics, Technologies, and Devices
New to Insight Pharma Reports is: Ocular Disorders: Rising Therapeutics, Technologies, and Devices. This report covers several companies and their approach to targeting ocular diseases including wet and dry age-related macular degeneration (AMD) while also providing alternative therapeutic options for various ocular complications.
Cancer Immunotherapy Report
Cancer Immunotherapy: immune checkpoint inhibitors, cancer vaccines, and adoptive T-cell therapies, published by Insight Pharma reports and written by Allan B. Haberman focuses on the rising potential for the newest and most promising of cancer treatments: cancer immunotherapy. Cancer immunotherapy was once just a dream in the minds of physicians, clinicians and patients, but only recently (2010s era) has it actually been within reasonable reach. Cancer Immunotherapy: immune checkpoint inhibitors, cancer vaccines, and adoptive T-cell therapies covers three principle therapies that have been in the works for cancer patients.